Treatment options for second-stage gambiense human African trypanosomiasis

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 11, 2014, Pages 1407-1417

  Eperon, Gilles ^a   Balasegaram, Manica ^a   Potet, Julien ^a   Mowbray, Charles ^a   Valverde, Olaf ^a   Chappuis, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

eflornithine; fexinidazole; gambiense; human African trypanosomiasis; melarsoprol; nifurtimox; oxaborole; SCYX 7158; second stage; sleeping sickness

Indexed keywords

2,5 BIS(4 AMIDINOPHENYL)FURAN; ARSANILIC ACID; EFLORNITHINE; FEXINIDAZOLE; MELARSOPROL; NIFURTIMOX; ORGANOBORON DERIVATIVE; ORNITHINE DECARBOXYLASE; PAFURAMIDINE; PENTAMIDINE; SCYX 1330682; SCYX 1608210; SCYX 7158; SURAMIN; TRYPARSAMIDE; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT;

AFRICAN TRYPANOSOMIASIS; ANEMIA; ANOREXIA; ANTIPROTOZOAL ACTIVITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; COMA; CONVULSION; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENCEPHALOPATHIC SYNDROME; ENZYME INHIBITION; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEIZURE; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREMOR; TRYPANOSOMA BRUCEI; VOMITING; ANIMAL; DISEASE COURSE; DRUG COMBINATION; PARASITOLOGY; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

ANIMALS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 84911472243     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.959496     Document Type: Review

References (70)

1. Burri C, Chappuis F, Brun R. Human African trypanosomiasis. In: Farrar J, Hotez PJ, Junghanss T, Gagandeep K, Lalloo D, White NJ, editors. Manson's Tropical Diseases (23). W.B. Saunders Ltd; London, UK: 2014. p. 606-21
2. World Health Organization. Working to overcome the global impact of neglected diseases: first WHO report on neglected tropical diseases. WHO; Geneva, Switzerland: 2010. p. 82-90
3. Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011; 5(2):e1007
4. Pepin J, Meda HA. The epidemiology and control of human African trypanosomiasis. Adv Parasitol 2001;49:71-132
5. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO report on neglected tropical diseases. WHO; Geneva, Switzerland: 2013. p. 60-6
6. Tong J, Valverde O, Mahoudeau C, et al. Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl Health 2011;5:7
7. Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005;18(1):133-46.
8. World Health Organization. Control and surveillance of human African trypanosomiasis. WHO Technical Report Series. (984). WHO; Geneva, Switzerland: 2013.
9. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97(1):55-64.
10. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978;58(3):169-76
11. Jamonneau V, Ilboudo H, Kabore J, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 2012.6(6):e1691
12. Ollivier G, Legros D. Human African trypanosomiasis: a history of its therapies and their failures. Trop Med Int Health 2001;6(11):855-63.
13. Friedheim EA. Mel B in the treatment of tryparsamide resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroun. Am J Trop Med Hyg 1951;31(2):218-35
14. Pepin J, Mpia B. Trypanosomiasis relapse after melarsoprol therapy. Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 2005;11(6):921-7
15. Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994;33:1-47
16. Fairlamb AH, Carter NS, Cunningham M, Smith K. Characterisation of melarsen-resistant Trypanosoma brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 1992;53(1-2):213-22
17. Pepin J, Mpia B. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg 2006;100(5):437-41
18. Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-Day melarsoprol schedule for the treatment of late-stage human african trypanosomiasis: confirmation from a Multinational Study (Impamel II). J Infect Dis 2005;191(11): 1922-31
19. Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000;355(9213): 1419-25
20. Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999;93(4): 439-42
21. Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001;6(5):330-4
22. Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ 2006;84(10):783-91
23. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007;195(3):322-9
24. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001;6(5):390-400
25. Eperon G, Schmid C, Loutan L, Chappuis F. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. Acta Trop 2007;101(1):31-9
26. Seixas J. Investigations on the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. Instituo de Higiene e medicina tropical. 2004
27. Van Nieuwenhove S, Schechter PJ, Declercq J, et al. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alphadifluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985;79(5): 692-8
28. Bacchi CJ, Nathan HC, Hutner SH, et al. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980;210(4467):332-4
29. Iten M, Mett H, Evans A, et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alphadifluoromethylornithine. Antimicrob Agents Chemother 1997;41(9):1922-5
30. Bacchi CJ, Garofalo J, Ciminelli M, et al. Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol 1993;46(3):471-81
31. Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008; 336(7646):705-8
32. Milord F, Pepin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992;340(8820):652-5
33. Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005;41(5):748-51
34. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374(9683):56-64.
35. Pepin J, Khonde N, Maiso F, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 2000;78(11):1284-95
36. Burri C, Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 2003; 90(Supp 1):S49-52
37. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011;286(15): 13088-95
38. Janssens PG, De Muynck A. Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 1977;57(4-5):475-80
39. Moens F, De Wilde M, Ngato K. Clinical trial of nifurtimox in human African trypanosomiasis. Ann Soc Belg Med Trop 1984;64(1):37-43
40. Pepin J, Milord F, Mpia B, et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 1989;83(4): 514-17
41. Pepin J, Milord F, Meurice F, et al. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992;86(3): 254-6
42. Van Nieuwenhove S, Declercq J. Nifurtimox (lampit) treatment in late stage of gambiense sleeping sickness. Presented at 17th meeting of International Scientific Council for Trypanosomiasis Research and control; Arusha, Tanzania; 1981. p. 206-8
43. Van Nieuwenhove S. Gambiense sleeping sickness: re-emerging and soon untreatable? Bull World Health Organ 2000;78(11): 1283
44. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006;1(8):e39
45. Checchi F, Piola P, Ayikoru H, et al. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 2007;1(2):e64
46. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007;152(8):1155-71
47. Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007;45(11):1435-42
48. Franco JR, Simarro P, Diarra A, et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med 2012;3:1-9
49. Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis 2012;6(11): e1920
50. Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clin Infect Dis 2013;56(2):195-203
51. Yun O, Priotto G, Tong J, et al. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010;4(5):e720
52. Coyne PE Jr. The eflornithine story. J Am Acad Dermatol 2001;45(5):784-6
53. Simarro PP, Franco J, Diarra A, et al. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 2012;139(7): 842-6
54. Moran M, Strub-Wourgaft N, Guzman J, et al. Registering new drugs for low-income countries: the African challenge. PLoS Med 2011;8(2):e1000411
55. Torreele E, Bourdin Trunz B, Tweats D, et al. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2010;4(12): e923
56. Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 2014;53(6):565-80
57. Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011; 5(6):e1151
58. Trunz BB, Jedrysiak R, Tweats D, et al. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
59. Frearson JA, Brand S, McElroy SP, et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010;464(7289):728-32
60. Brand S, Cleghorn LA, McElroy SP, et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 2012;55(1):140-52
61. Wenzler T, Yang S, Braissant O, et al. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis. Antimicrob Agents Chemother 2013;57(11):5330-43
62. Wenzler T, Yang S, Patrick DA, et al. In vitro and in vivo evaluation of 28dap010, a novel diamidine for treatment of second-stage African sleeping sickness. Antimicrob Agents Chemother 2014;58(8): 4452-63
63. GlaxoSmithKline. Partnerships: neglected tropical diseases. Available from: www.gsk. com/partnerships/neglected-tropical-diseases. html
64. Novartis. Novartis Institute for Tropical Diseases (NITD). Available from: www.nibr.com/research/developing-world/NITD/index.shtml
65. Büscher P, Gilleman Q, Lejon V. Rapid diagnostic test for sleeping sickness. N Engl J Med 2013;368(11):1069-70
66. Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-KSeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2014;2(6):e359-63. Published online May 9, 2014 Available from: http://dx.doi.org/10.1016/S2214-109X(14)70203-7
67. Robays J, Lefevre P, Lutumba P, et al. Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 2007;12(2):290-8
68. Palmer JJ, Surur EI, Goch GW, et al. Syndromic algorithms for detection of gambiense human African trypanosomiasis in South Sudan. PLoS Negl Trop Dis 2013; 7(1):e2003
69. World Health Organization. Stakeholders call on WHO to lead a network aimed at elimination of human African trypanosomiasis (2014). Available from: www.who.int/trypanosomiasis-african/meeting-declaration-2014-intro/en/
70. Target product profile of new treatments for human African trypanosomiasis. Available from: www.dndi.org/diseases-projects/diseases/hat/target-product-profile.html